Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Obesity01:24

Obesity

1.3K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.3K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

242
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
242
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

263
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
263
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

176
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
176
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

602
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
602
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

927
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
927

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unexplained hypoventilation in adults: autoimmune encephalitis and beyond.

The European respiratory journal·2026
Same author

Positive Airway Pressure Therapy for Pulmonary Hypertension Associated with Sleep-disordered Breathing.

Archivos de bronconeumologia·2026
Same author

Usefulness of the S3-NIV patient questionnaire added to telemonitoring data for the first 6 months of home non-invasive ventilation.

Respiration; international review of thoracic diseases·2026
Same author

Mechanism-directed pharmacotherapy in obstructive sleep apnea: insights from aroxybutynin/atomoxetine (AD109) intervention in the SynAIRgy trial.

American journal of respiratory and critical care medicine·2026
Same author

Correction: Treatment preferences for comorbid obesity and obstructive sleep apnea (PRO-CON OSA) survey: Patient and provider preferences for CPAP and/or tirzepatide.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine·2026
Same author

Hypercapnia-Regulated Molecular Pathways: Mechanistic Insights Into CO₂-Driven Cellular Signaling and Therapeutic Implications.

Cell biochemistry and function·2026

Related Experiment Video

Updated: Jan 27, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

957

Obesity hypoventilation syndrome.

Juan F Masa1,2,3, Jean-Louis Pépin4,5, Jean-Christian Borel4,6

  • 1San Pedro de Alcántara Hospital, Cáceres, Spain fmasa@separ.es.

European Respiratory Review : an Official Journal of the European Respiratory Society
|March 16, 2019
PubMed
Summary
This summary is machine-generated.

Obesity hypoventilation syndrome (OHS) is a condition characterized by obesity, daytime hypercapnia, and sleep-disordered breathing. Treatments like CPAP and NIV improve symptoms and quality of life.

More Related Videos

Acupoint Catgut Embedding Therapy for Abdominal Obesity Treatment
05:18

Acupoint Catgut Embedding Therapy for Abdominal Obesity Treatment

Published on: November 22, 2024

1.4K
An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

1.4K

Related Experiment Videos

Last Updated: Jan 27, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

957
Acupoint Catgut Embedding Therapy for Abdominal Obesity Treatment
05:18

Acupoint Catgut Embedding Therapy for Abdominal Obesity Treatment

Published on: November 22, 2024

1.4K
An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

1.4K

Area of Science:

  • Pulmonary Medicine
  • Sleep Medicine
  • Critical Care

Background:

  • Obesity hypoventilation syndrome (OHS) affects approximately 0.4% of adults.
  • Diagnosis involves obesity (BMI ≥30 kg·m⁻²), daytime hypercapnia (PaCO₂ ≥45 mmHg), and sleep-disordered breathing.
  • OHS results from obesity-related respiratory changes, altered respiratory drive, and sleep breathing abnormalities.

Purpose of the Study:

  • To define Obesity Hypoventilation Syndrome (OHS).
  • To outline diagnostic criteria and common comorbidities.
  • To review current treatment modalities and management strategies.

Main Methods:

  • Diagnosis confirmed by arterial blood gases and sleep studies.
  • Exclusion of other disorders causing alveolar hypoventilation.
  • Assessment of comorbidities, including cardiovascular and metabolic conditions.

Main Results:

  • Continuous positive airway pressure (CPAP) and noninvasive ventilation (NIV) improve OHS symptoms, gas exchange, and sleep quality.
  • CPAP is first-line for OHS with severe obstructive sleep apnea (OSA).
  • NIV is preferred for OHS with hypoventilation and mild/no OSA, and for acute hypercapnic respiratory failure.

Conclusions:

  • OHS management requires addressing comorbidities through medication and rehabilitation.
  • NIV is crucial for acute hypercapnic respiratory failure in OHS patients.
  • Tailored ventilation strategies (CPAP vs. NIV) are essential for optimal OHS treatment outcomes.